Every 8-K that Aspira Womens Health Inc (AWHL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AWHL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AWHL filings page.
Aspira Women’s Health Inc. entered into a Subordinated Business Loan and Security Agreement with Agile Lending, LLC as lead lender and Agile Capital Funding, LLC as collateral agent. The agreement provides a secured term loan documented by a Subordinated Secured Promissory Note dated as of July 1, 2026.
The Note was issued in a principal amount of $1,050,000, carries scheduled interest charges of $441,000 assuming timely payments, and is scheduled to mature on January 26, 2027. Payment under the Note is expressly subordinated to all Senior Indebtedness. The company and certain subsidiary co‑borrowers granted a continuing security interest in substantially all of their personal property, including goods, accounts, equipment, inventory, general intangibles (including intellectual property), instruments, chattel paper, deposit accounts, other investment property, and related proceeds, subject to customary exclusions. A financing statement may be filed only upon an event of default.
Aspira plans to use the term loan proceeds to refinance debt from a loan received in January and for general corporate purposes. The agreement contains customary affirmative and negative covenants, with certain financial covenant requirements waived, and specifies events of default such as payment failures, covenant breaches, material adverse changes, specified liens, judgments, and insolvency events. Upon default, lenders may accelerate obligations and exercise remedies, including repossession of collateral. The agreement is governed by Virginia law with exclusive jurisdiction in Virginia courts.
Aspira Women’s Health Inc. filed an amended report detailing the separation terms for former Chief Executive Officer Michael Buhle, who ceased serving as CEO effective June 17, 2026. The company and Mr. Buhle entered into a Separation Agreement and General Release on June 27, 2026, which becomes effective after a seven-day revocation period.
Under the agreement, Mr. Buhle will receive cash severance of $200,000, equal to six months of base salary, paid in installments, plus company-paid COBRA health and dental premiums for six months. The company will also accelerate vesting of stock options for 64,583 shares at an exercise price of $0.07 per share, exercisable for 90 days after the effective date, while all other unvested awards are forfeited.
Any shares from these options are subject to a 90-day lock-up from each exercise, a daily sale cap of 2,500 shares, a minimum sale price of $0.45 per share, and broker and notice requirements. The agreement includes mutual releases, non-disparagement, confidentiality, and continued restrictive covenants, and the company reiterates that Mr. Buhle’s departure did not result from any disagreement over operations, policies, or practices.
Aspira Women’s Health Inc. announced a leadership change, with Michael Buhle ceasing to serve as Chief Executive Officer on June 17, 2026. The board appointed its Chairman, John Fraser, as Interim Chief Executive Officer and Principal Executive Officer while it conducts a search of internal and external candidates.
The company states that Mr. Buhle’s departure was not due to any disagreement about operations, policies, or practices. Aspira and Mr. Buhle are discussing a separation agreement, and the company plans to file an amendment disclosing the material terms within four business days after they are determined.
Aspira Women’s Health Inc. reported the results of its 2026 annual stockholder meeting. Of 43,500,411 common shares entitled to vote as of the record date, 27,144,522 shares were represented, a quorum of 62.40%.
Stockholders elected all six director nominees for one‑year terms and approved, on an advisory basis, the compensation of the company’s named executive officers. They also approved an amendment to the 2019 Stock Incentive Plan to add 5,000,000 shares, bringing the total shares authorized under the plan to 9,532,818.
In addition, stockholders ratified the selection of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2026.
Aspira Women’s Health Inc. entered into securities purchase agreements for a private placement of equity and warrants with accredited and institutional investors. The company issued 3,300,000 shares of common stock and common warrants to purchase up to 4,455,000 additional shares at $0.45 per share and accompanying warrant.
The common warrants are exercisable immediately at $0.75 per share and have a three-year term. The private placement closed on June 5, 2026 and generated approximately $1.485 million in gross proceeds, which the company plans to use for working capital and general corporate purposes. Purchasers received customary registration rights for the shares and warrant shares.
Aspira Women’s Health Inc. entered into a Master Collaboration and License Agreement with Cleveland Clinic Foundation effective May 20, 2026. The companies will jointly pursue biomedical research and development projects, including biomarker discovery and AI-driven diagnostic model development in women’s health.
Aspira will pay Cleveland Clinic a non-refundable, non-creditable partnering fee of $125,000, with $50,000 due within 30 days of the effective date and $25,000 on each of the first three anniversaries. The initial term is five years, with mutual extension rights, and the agreement includes customary provisions on confidentiality, healthcare law compliance, and indemnification.
Aspira Women’s Health Inc. appointed John Strahley as Chief Financial Officer and Chief Accounting Officer, effective April 27, 2026, replacing Brian Hungerford, who stepped down for personal reasons. Strahley will work in a fractional role, committing at least twenty hours per week.
Under his Executive Employment Agreement, Strahley receives an annualized base salary of $167,000 and is eligible for the company’s 401(k) plan but not for group insurance benefits. The Board will approve stock options for 70,000 shares at fair market value on the grant date, with 25% vesting ninety days after his start date and the remainder vesting monthly over the following nine months. Any unvested options fully vest upon a Change in Control, and his at-will employment includes no severance beyond accrued obligations.
Aspira Women’s Health Inc. filed an amended report to provide the full Laboratory Services Agreement it entered into with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories. The agreement is effective as of December 16, 2025 and had previously been disclosed as a material definitive agreement.
The amendment mainly adds the agreement as Exhibit 10.1 after completing redactions of private or confidential information. No financial results or other business updates are included beyond this contract filing.
Aspira Women’s Health Inc. entered into a new subordinated secured term loan agreement with Agile Lending, LLC and other lenders. The company issued a subordinated secured promissory note with $1,050,000 principal and total interest charges of $441,000 (assuming timely payments), maturing on August 26, 2026. The loan is subordinated to all senior indebtedness and is secured by a continuing security interest in substantially all personal property of the company and certain subsidiary co-borrowers, subject to customary exclusions. Proceeds will be used for general corporate purposes, and the agreement contains customary covenants and events of default that allow lenders to accelerate obligations and enforce on collateral if triggered.
Aspira Women’s Health Inc. filed a current report to note that it has shared updated investor information with the market. On December 29, 2025, the company published an investor presentation on its website, providing a slide deck that outlines its business and related information for shareholders and other stakeholders. This slide deck is included as Exhibit 99.1 to the report. The filing is made under Regulation FD, which is intended to ensure that all investors have access to the same key information at the same time.
Aspira Women’s Health Inc. entered into a purchase agreement with Lincoln Park Capital Fund under which Lincoln Park committed to buy up to $10.0 million of Aspira’s common stock over up to 24 months, at Aspira’s discretion. Purchases will occur after a resale registration statement is declared effective and a final prospectus is filed.
On eligible days with a closing price above $0.10, Aspira may direct “Regular Purchases” of up to 50,000 shares, rising to 75,000 or 100,000 shares at higher price thresholds, each capped at $500,000. The purchase price is set at 95% of the lower of the sale price on the purchase date or the average of the three lowest closing prices over the prior ten business days, and may be supplemented by “Accelerated Purchases” based on trading volume.
Lincoln Park received commitment shares valued at 3.0% of the $10.0 million commitment, issued under private placement exemptions. The agreement limits Lincoln Park’s beneficial ownership to 4.99%, adjustable up to 9.99% with notice, includes no financial covenants, and generally restricts Aspira from entering other equity line arrangements during the 24‑month term.
Aspira Women’s Health entered into a Laboratory Services Agreement with Mayo Clinic Laboratories effective December 16, 2025. Aspira will perform its Ova1Plus (Ova1 and Overa) and OvaWatch ovarian cancer risk assessment tests for Mayo on a non-exclusive, as-requested basis for clinical use.
The initial term runs for five years with automatic one-year renewals, and either party may terminate for convenience with at least 90 days prior written notice or earlier for cause. Mayo will list the Aspira tests in its catalog, handle ordering, results delivery, and billing, while Aspira invoices Mayo at fixed fees during the initial term, subject to agreed adjustments. The agreement includes customary provisions on confidentiality, healthcare law compliance, insurance, indemnification, and non-exclusivity.
Aspira Women’s Health Inc. filed a Form 8-K announcing it issued a press release reporting financial results for the three and nine months ended September 30, 2025. The press release is provided as Exhibit 99.1.
The filing lists the company’s common stock trading on the OTC QX Market under the symbol AWHL.
Aspira Women’s Health Inc. filed an amended Form 8-K to correct the form of its Amended and Restated Series A Common Stock Warrant. The company stated that the version previously included with its September 25, 2025 disclosure inadvertently listed an incorrect termination date. The corrected warrant form is filed as Exhibit 4.1 and incorporated by reference.
The amendment is reported under Item 1.01 (Entry into a Material Definitive Agreement), with Item 3.02 (Unregistered Sales of Equity Securities) incorporating Item 1.01 by reference. The earliest event date is September 19, 2025.
Aspira Women’s Health Inc. reported that on October 14, 2025 it upgraded its trading venue to OTCQX from the OTCQB Venture Market. The company now trades on OTCQX under the symbol AWHL.
Aspira Women’s Health Inc. entered into an amendment to its March 2025 securities purchase agreement covering a prior $1,370,000 private placement of Senior Secured Convertible Promissory Notes, all of which have now converted into units of common stock and warrants. The amendment requires Aspira to file a Form S-1 registration statement by September 30, 2025 to register the common shares and the shares underlying the warrants issued in that financing.
The amendment also grants the participating purchasers, as a group, the right to appoint up to three directors to the board until the earlier of specified time and listing milestones or until their aggregate warrant holdings fall below fifty percent. In connection with this change, Aspira issued Amended and Restated Series A Common Stock Warrants, which now have a fixed exercise price of $0.35 per share, must be exercised for cash, have their term extended to six years from issuance, and begin to be exercisable six months after the issuance date.
Aspira Women’s Health Inc. entered into securities purchase agreements for a private placement of 6,550,000 shares of common stock and accompanying warrants to purchase up to 4,912,500 additional shares. The securities were sold at $0.45 per share of common stock plus accompanying warrant.
The warrants are exercisable immediately at $0.75 per share and have a five-year term from issuance. The transaction closed on September 17, 2025, generating approximately $2.95 million in gross proceeds, which the company plans to use for working capital and general corporate purposes.